Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
3.755
-0.265 (-6.59%)
Nov 7, 2025, 1:18 PM EST - Market open
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $244.00K in the quarter ending June 30, 2025, with 190.48% growth. This brings the company's revenue in the last twelve months to $646.00K, down -33.47% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.
Revenue (ttm)
$646.00K
Revenue Growth
-33.47%
P/S Ratio
194.21
Revenue / Employee
$11,333
Employees
57
Market Cap
115.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | -568.72% |
| Mar 31, 2023 | -227.00K | -1.34M | -120.47% |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VTGN News
- 2 days ago - Vistagen to Participate in Stifel Healthcare Conference 2025 - Business Wire
- 4 days ago - Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 9 days ago - Vistagen Appoints Paul Edick to its Board of Directors - Business Wire
- 22 days ago - Vistagen to Present at The Menopause Society 2025 Annual Meeting - Business Wire
- 2 months ago - Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - Business Wire
- 3 months ago - Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - Business Wire
- 3 months ago - Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 - Business Wire